간행물

생화학분자생물학회입니다.


BMB Reports

New therapeutic approach with extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome

  • 작성자

    Aram Kim
  • 작성일자

    2022-07-19
  • 조회수

    81
Name: Aram Kim ( arkim@kuh.ac.kr )
2017-presentAssociate Professor, Kunkuk University medical center
2015-2017Clinical Fellowship, Urology at Asan Medical Center
2013-2015Ph.D, Ulsan Univ. school of medicine
2011-2015Resident, Urology at Asan Medical Center

New therapeutic approach with extracellular vesicles from stem cells for intestinal cystitis/bladder pain syndrome

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disorder characterized by suprapubic pain and urinary symptoms such as urgency, nocturia, and frequency. The prevalence of IC/BPS is increasing as diagnostic criteria become more comprehensive. Conventional pharmacotherapy against IC/BPS has shown suboptimal effects, and consequently, patients with end-stage IC/BPS are subjected to surgery. The novel treatment strategies should have two main functions, anti-inflammatory action and the regeneration of glycosaminoglycan and urothelium layers. Stem cell therapy has been shown to have dual functions. Mesenchymal stem cells (MSCs) are a promising therapeutic option for IC/BPS, but they come with several shortcomings, such as immune activation and tumorigenicity. MSC-derived extracellular vesicles (MSC-EVs) hold numerous therapeutic cargos and are thus a viable cell-free therapeutic option. In this review, we provide a brief overview of IC/BPS pathophysiology and limitations of the MSC-based therapies. Then we provide a detailed explanation and discussion of therapeutic applications of EVs in IC/BPS as well as the possible mechanisms. We believe our review will give an insight into the strengths and drawbacks of EV-mediated IC/BPS therapy and will provide a basis for further development.


BMB Rep. 2022 May;55(5):205-212.
https://pubmed.ncbi.nlm.nih.gov/35410640/